All Blogs
Apr 24, 2025
FDA Approves Simplera Sync™ Sensor for MiniMed™ 780G System; BVI Medical Secures FDA 510(k) Clearance for Leos™ Laser Endoscopy System in Ophthalmology; Surmodics Announces TRANSCEND Trial Data Supporting SurVeil™ Drug-Delivery Platform; Elutia Launches EluPro™ Registry Study to Gather Real-World Clinical Data; BD Launches Next-Generation AI-Driven Hemodynamic Monitoring and Industry-First Bioabsorbable Mesh for Umbilical Hernia Repair
New Simplera Sync™ Sensor for the MiniMed™ 780G System Secured FDA Approval, Advancing Insulin Delivery On April 18, 2025, Medtronic plc, a global leader in healthcare technology, received FDA approval for its Simplera Sync™ sensor for integration with the MiniMed™ 780G system. This approval enhances the f...
Read More...
Apr 23, 2025
Exploring the Impact of AI in Mental Health: How it is Going to Revolutionize Diagnosis and Treatment for a Better Tomorrow?
One in every eight people worldwide lives with a psychiatric disorder—a staggering statistic that underscores the deep and growing impact of mental illness on global health. The mental health crisis has evolved into a pressing public health emergency, fueled by increasing social pressures, lifestyle changes, enviro...
Read More...
Apr 22, 2025
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead’s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest’s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure’s AMT-130 Granted FDA Breakthrough for Huntington’s; NeuroNOS’ BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria Regeneron Pharmaceuticals and Sanofi have announced that the FDA has approved DUPIXENT (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous...
Read More...
Apr 21, 2025
ACC.25 Highlights: Groundbreaking Advances in Cardiovascular Medicine and Emerging Therapeutics
The American College of Cardiology’s 74th Annual Scientific Session and Expo (ACC.25) convened from March 29 to March 31, 2025, in Chicago, Illinois, serving as a pivotal platform for the latest advancements in cardiovascular medicine. The conference attracted over 280 companies and organizations, showcasing innova...
Read More...
Apr 18, 2025
Groundbreaking Alzheimer’s Therapies: From Pipeline to Patient Care
The Alzheimer's and Parkinson's Diseases (AD/PD) 2025 International Conference, conducted in April in Vienna, Austria, and online, stands as a pivotal event in neurodegenerative disease research. This hybrid gathering brings together global experts to delve into the latest advancements in Alzheimer’s and Parkinson’...
Read More...
Apr 17, 2025
Edwards’ SAPIEN M3 Becomes First Transfemoral TMVR System to Receive CE Mark; Terumo Neuro Receives FDA Clearance for Carotid Stent System; Microbot Medical Reports Complete Robotic Navigation Success in LIBERTY® System Pivotal Trial; J&J MedTech Marks Milestone with First OTTAVA™ Robotic Surgeries; Baxter Introduces Room-Temperature Hemopatch for Faster Surgical Hemostasis; Merit Medical Introduces the Ventrax™ Delivery System
Edwards' SAPIEN M3 Received CE Mark as the World’s First Transfemoral TMVR System On April 14, 2025, Edwards Lifesciences Corporation announced that its SAPIEN M3 mitral valve replacement system had received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe)...
Read More...
Apr 16, 2025
Non-Surgical Body Contouring: What’s Fueling Its Growth in Aesthetic Medicine?
In the ever-evolving world of aesthetic medicine, non-surgical body contouring has emerged as a beacon of innovation, offering patients a path to their ideal physique without the scalpel. Imagine a treatment that melts away stubborn fat, tightens skin, and even tones muscle—all while you relax, with no downtime to ...
Read More...
Apr 15, 2025
Cellenkos’ CK0801 Granted FDA Orphan Drug Status for Aplastic Anemia; Mirum’s LIVMARLI Gets FDA Nod for Tablet Formulation; SynOx’s Emactuzumab Earns FDA Fast Track for TGCT; Bristol Myers Squibb’s OPDIVO + YERVOY Combo Approved by FDA for First-Line Advanced Liver Cancer; Soleno Launches VYKAT XR, the First FDA-Approved Therapy for PWS-Related Hyperphagia
Cellenkos’ CK0801 Granted FDA Orphan Drug Designation for Aplastic Anemia Cellenkos® Inc. announced that the FDA has granted Orphan Drug Designation to CK0801, its off-the-shelf, allogeneic T regulatory (Treg) cell therapy, for the treatment of Aplastic Anemia—a rare and life-threatening bone marrow failure diso...
Read More...
Apr 14, 2025
Redefining Liver Disease in the Metabolic Era: From NASH to MASH and the Rise of Obesity‐targeted Therapies
The paradigm shift from Non‐alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction–associated Steatohepatitis (MASH) reflects a deeper understanding of the pathophysiology underpinning liver injury in the context of obesity, diabetes, and metabolic syndrome. This evolving nomenclature from NASH to MASH is more t...
Read More...
Apr 11, 2025
Prader-Willi Syndrome Drug Market Heats Up: 5 Upcoming Challengers to Soleno’s VYKAT XR
Since the FDA approved recombinant human growth hormone (rhGH) for Prader-Willi syndrome in 2000, numerous companies have faced challenges in developing more advanced treatments for hyperphagia, the uncontrollable hunger associated with PWS. However, in March 2025, Soleno Therapeutics marked a major milestone wi...
Read More...